Retatrutide: The Triple Agonist in GLP-1 Research

Retatrutide (LY3437943) is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the leading edge of incretin-based pharmacology research and demonstrating the largest weight reduction magnitudes reported in a Phase 2 trial to date. This post summarizes peer-reviewed findings on its receptor pharmacology, clinical trial data, and mechanistic distinctions from earlier dual-agonist compounds — all content is presented for research reference only and does not constitute medical advice or guidance for human use.

From Single to Triple Agonism: The Incretin Pharmacology Evolution

GLP-1 Receptor Agonism: The Foundation

The GLP-1 (glucagon-like peptide-1) receptor agonist class established that augmenting postprandial incretin signaling produces clinically meaningful reductions in blood glucose and body weight. GLP-1 receptor activation reduces appetite through central hypothalamic circuits, slows gastric emptying, and enhances pancreatic beta cell glucose-stimulated insulin secretion while suppressing glucagon.

Adding GIP: The Tirzepatide Precedent

Tirzepatide (LY3298176), approved by the FDA in 2022 under the brand name Mounjaro, combined GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, demonstrating superior glycemic control and weight loss compared to semaglutide in the SURPASS trial program. GIP receptor activation contributes to incretin amplification and has been shown to modulate adipogenesis and energy storage in adipose tissue through mechanisms distinct from GLP-1.

The Glucagon Receptor: Retatrutide's Additional Dimension

Retatrutide adds glucagon receptor agonism as a third dimension. Glucagon is classically associated with hepatic glucose production and glycogenolysis, making its inclusion in a metabolic therapeutic appear counterintuitive given the standard goal of lowering glucose. However, glucagon receptor activation also significantly increases resting energy expenditure by stimulating hepatic fat oxidation, promoting thermogenesis, and reducing appetite through direct central nervous system effects. At the balanced dose ratios achieved with retatrutide, the glucagon receptor-mediated glycemic elevations are offset by the dominant GLP-1 and GIP insulinotropic effects, while the metabolic and energy expenditure benefits of glucagon activation are preserved.

Retatrutide: LY3437943 Structure and Receptor Pharmacology

Retatrutide is a fatty acid-conjugated peptide (similar to the semaglutide design for albumin binding and extended half-life) that achieves once-weekly dosing through reversible albumin binding mediated by a C18 fatty diacid linker. The peptide backbone is engineered to achieve balanced, simultaneous agonism at all three receptor types — GLP-1R, GIPR, and GCGR — without the receptor selectivity biases that characterize earlier dual agonists.

In radioligand binding and functional cAMP accumulation assays, retatrutide demonstrates sub-nanomolar potency at all three receptors, with GLP-1R and GIPR activity comparable to the endogenous peptide ligands and GCGR activity approximately 10-fold lower (Bokvist et al., preclinical pharmacology data presented at American Diabetes Association Scientific Sessions, 2022). This partial relative glucagon activity is considered important for achieving energy expenditure benefits without excessive glycemic liability.

SURMOUNT-5 Phase 2 Trial: Jastreboff et al. 2023

Trial Design and Population

The landmark Phase 2 trial of retatrutide in obesity was published by Jastreboff et al. in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with a body mass index (BMI) of 30 or greater (or ≥27 with at least one weight-related comorbidity), without type 2 diabetes, randomized to five dose groups (1 mg, 4 mg, 8 mg, or 12 mg weekly, with escalation protocols) or placebo over 48 weeks.

Weight Loss Results

The primary efficacy endpoint was percent change in body weight from baseline at week 48. Results were as follows:

12 mg dose group: Mean body weight reduction of 24.2% from baseline, the highest weight loss magnitude reported in a pharmacological weight loss trial to that date
8 mg dose group: Mean body weight reduction of approximately 22.8%
4 mg dose group: Mean body weight reduction of approximately 17.5%
Placebo group: Mean change of approximately −2.1%

All active dose groups achieved statistically significant weight loss versus placebo (p < 0.001 for all comparisons). Notably, the weight loss trajectory in the higher-dose groups had not plateaued at week 48, suggesting that continued treatment might yield further weight reductions — a finding that distinguished retatrutide from earlier agents for which plateau was apparent within the trial window.

Safety and Tolerability

The safety profile was consistent with the GLP-1 receptor agonist class: the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), predominantly mild-to-moderate in severity, and most frequent during dose escalation. No unexpected safety signals were identified in the 48-week observation period. Rates of discontinuation due to adverse events were dose-dependent, ranging from 8% (1 mg) to 16% (12 mg), compared to 3% in the placebo group.

Modest increases in heart rate (3–5 bpm, similar to the GLP-1 agonist class effect) were observed. Importantly, despite the glucagon receptor component, no clinically significant adverse liver function signals emerged in the 48-week period, an area of potential concern given glucagon's hepatic metabolic effects.

Cardiovascular and Metabolic Effects

Cardiometabolic Biomarker Changes

Beyond weight loss, the SURMOUNT-5 trial documented significant improvements in cardiometabolic markers in the active treatment groups:

Waist circumference: Reductions of 20–23 cm in the highest dose groups
Blood pressure: Significant reductions in systolic and diastolic blood pressure relative to placebo
Lipid profiles: Reductions in triglycerides and LDL-cholesterol, with increases in HDL-cholesterol
Insulin resistance: Substantial reductions in fasting insulin and HOMA-IR scores

The investigators noted that the magnitude of these metabolic improvements was consistent with the degree of weight loss achieved, and that disentangling weight-loss-mediated from direct receptor-mediated metabolic effects would require mechanistic substudy designs.

Glucagon Receptor Contribution to Energy Expenditure

Preclinical studies comparing matched-dose GLP-1/GIP dual agonists with GLP-1/GIP/glucagon triple agonists at equal GLP-1 and GIP activity have attributed an approximately 20–30% additional reduction in body weight to the glucagon receptor component, mediated through increased resting energy expenditure and enhanced fatty acid oxidation in the liver (Finan et al., Science Translational Medicine, 2015). These preclinical data provided the mechanistic hypothesis tested by retatrutide's Phase 2 design.

Comparison to Tirzepatide: Mechanistic Distinctions

Both retatrutide and tirzepatide target GLP-1R and GIPR, but the addition of glucagon receptor agonism distinguishes retatrutide mechanistically. Research in diet-induced obesity models has suggested that the glucagon component adds an energy expenditure dimension to weight loss that is not captured by dual GLP-1/GIP agonism alone, potentially explaining the incrementally larger weight loss observed in the retatrutide Phase 2 data relative to tirzepatide's SURPASS-3 and SURMOUNT-1 trial results.

Tirzepatide achieved 20–22% weight loss in SURMOUNT-1 at the highest dose, while retatrutide achieved 24% at 12 mg in SURMOUNT-5 — a difference that, while modest in absolute terms, suggests the glucagon receptor contribution is pharmacologically meaningful, consistent with preclinical predictions.

Phase 3 retatrutide trials (TRIUMPH program) are ongoing with cardiovascular outcome endpoints, type 2 diabetes indication arms, and longer-duration data collection that will provide more definitive evidence on its long-term efficacy and safety profile.

For related compound research, see the semaglutide research overview and the tirzepatide dual agonist entry in this database.

All content on ClinicalPeptide.org is intended exclusively for research reference. No content constitutes medical advice, clinical guidance, or recommendations for human use.